Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders

Trial Profile

A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jan 2019

At a glance

  • Drugs Arsenic trioxide (Primary)
  • Indications Acute myeloid leukaemia; Acute myelomonocytic leukaemia; Acute promyelocytic leukaemia; Haematological disorders; Mantle-cell lymphoma; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Orsenix
  • Most Recent Events

    • 21 Dec 2018 Status changed from recruiting to active, no longer recruiting.
    • 17 Jun 2018 Results (n=7) presented at the 23rd Congress of the European Haematology Association
    • 08 Dec 2017 Planned number of patients changed from 50 to 20.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top